Managed Healthcare Executive2d
IBX Excludes Coverage of Drugs with Accelerated Approvals for 18 Months
Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...
Muscular Dystrophy News2d
Application finalized for DMD cell therapy CAP-1002, now deramiocel
Capricor's biologics license application for deramiocel (CAP-1002) is draws largely on the Phase 2 HOPE-2 trial and its ...
Pharmabiz6d
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy
Capricor Therapeutics seeks US FDA approval for deramiocel for the treatment of Duchenne muscular dystrophy: San Diego Saturday, January 4, 2025, 15:00 Hrs [IST] Capricor Therapeu ...
Capricor Therapeutics: Promising Advances in Duchenne Cardiomyopathy Treatment Drive Buy Rating
Maxim Group analyst Jason McCarthy maintained a Buy rating on Capricor Therapeutics (CAPR – Research Report) yesterday and set a price target ...
Managed Healthcare Executive6d
Capricor Completes BLA for Deramiocel for Duchenne Cardiomyopathy
Deramiocel is a cell therapy that has healing effects in muscle cells. If approved, deramiocel would be a once-quarterly ...
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA
Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.